2A PHARMA SECURES SEK 20 MILLION OF FUNDING

2A Pharma is very pleased to announce that it has raised SEK 20 million (USD 2.2M) from existing and new investors. This funding augments the previously raised SEK 27 million (USD 3M) and will enable2A Pharma to drive its leading vaccine candidate, 2AP01, a broad coverage prophylactic HPV vaccine formulated without adjuvants, through phase 1 clinical studies and support progress of the...

READ MORE

MEET US AT THE WORLD VACCINE CONGRESS IN WASHINGTON, DC, USA, 3-5 APRIL 2018

READ MORE

BIO EUROPE SPRING 2018

2A Pharma is overwhelmed by the positive responses we received from potential partners and collaborators at BIO-Europe Spring 2018. The conference was a resounding success from our perspective and we are looking forward to continuing the many exciting conversations that were started.

READ MORE

PRESS RELEASE: 2A PHARMA AB RAISES SEK 27 MILLION AND SIGNS EXCLUSIVE WORLDWIDE LICENSE AGREEMENT

[pdf-embedder url="https://2apharma.com/wp-content/uploads/2018/10/2A-Pharma-AB-Press-Release-2017-01-16.pdf" title="2A Pharma AB Press Release 2017-01-16"]
Open PDF...

READ MORE

ARTICLE ABOUT 2A PHARMA IN MEDWATCH

The following article was published in Danish pharma industry publication MedWatch on 16 January 2017.

READ MORE

EXCLUSIVE WORLDWIDE LICENSE AGREEMENT

Medigene AG today announced that it has granted an exclusive, worldwide license for the development and commercialization of its preclinical stage adeno-associated virus-like particles (AAVLPs) technology to 2A Pharma AB.

[pdf-embedder url="https://2apharma.com/wp-content/uploads/2016/12/Proposal-web-related-2A-Pharma..pdf"]
READ MORE

FIRST FINANCING ROUND CLOSED

2A Pharma AB today closed its first financing round, raising SEK 27 million from private angel investors. This new capital will enable us to take our first project, the AAVLP-HPV vaccine, through tothe end of phase I clinical studies. We are grateful for our investors’ support and trust.
...

READ MORE

2A PHARMA IS A REALITY

2A Pharma AB was incorporated in Sweden on 12 December 2016.

Søren Nielsen, CEO: “This marks the formal beginning of a new exciting venture and the team is very excited about the journey ahead.”

READ MORE